
Marc Benioff: AI and humans both have a role
Why it matters: Tech leaders are hedging their bets on AI: promising an eventual utopia in which everyone is productive and fulfilled, while at the same time reducing hiring, cutting jobs and voicing a range of near-term concerns.
The big picture: For most companies, the workforce transition is bumpy.
Over half of executives say that AI is "tearing their company apart," according to a study from March.
Benioff said that the main problem isn't the technology, it's that companies and workers aren't set up for the current pace of technological shift.
"Change management is extremely difficult for all these customers, because the level of transformation that is happening is unlike anything we've ever seen," Benioff said during a telephone interview last week.
At an Axios event at January's World Economic Forum in Davos, Benioff predicted that the next generation of CEOs will have to manage a workforce that is a mix of humans and AI agents.
Between the lines: Benioff sees the glass as more than half full, recently outlining an optimistic vision of our shared AI future in an op-ed in the Financial Times.
Being human is our "superpower," Benioff wrote.
"AI has no childhood, no heart. It does not love, does not feel loss, does not suffer. And because of that, it is incapable of expressing true compassion or understanding human connection."
Zoom in: Benioff says Salesforce's own experience can be instructive, pointing to shifts in the way the company handles both customer support and sales.
On the sales front, Benioff said the company plans to add thousands of sales staff even as it relies more on AI. All told, Benioff says the move will increase the company's sales capacity by 19%.
"For the last 26 years, the vast majority of the leads that we've received... we've not been able to call back," Benioff said.
Benioff says an AI agent called 4,000 potential new customers in one recent week.
The picture in support is more mixed. Benioff said the company has cut its costs by 17% by mixing in AI support agents.
Since the October 2024 introduction of Agentforce, Salesforce says help requests have been evenly split between humans and AI agents, each of which have handled roughly 1.2 million conversations.
"We've radically augmented our support personnel," Benioff said. "This is a great example of it really working."
Yes, but: Hiring for support workers has stagnated.
"There's no question that we're getting more productivity, which means that we're not growing our customer support this year," Benioff said. "We're also not radically reducing it."
Zoom out: Benioff isn't the only tech leader painting a rosy future while acknowledging it's likely to be a bumpy and uncertain path to get there.
Microsoft CEO Satya Nadella told employees last week that the company is nonetheless well-positioned and growing thanks to AI, despite laying off a further 9,000 workers on top of earlier cuts.
"Progress isn't linear. It's dynamic, sometimes dissonant, and always demanding," Nadella wrote in a memo.
Amazon has also been touting its AI prowess at the same time the company has said it expects to have a smaller corporate staff over time.
The bottom line: For Benioff, the future is growth. As long as companies can survive the growing pains.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
I missed Nvidia – could this be the next big US growth stock?
Let's be honest — most of us missed the boat on Nvidia (NASDAQ: NVDA). And by the time we realised just how vital graphics processing units (GPUs) would become to artificial intelligence (AI), the share price had already soared into the stratosphere. Over the past five years, the stock has climbed almost 1,600%. In the last six months alone, it's up almost 50%, adding over $1.5trn to its market value. It's now the most valuable company in the world, overtaking Microsoft and Apple in June. I have exposure to the stock through several ETFs and investment trusts, so I didn't entirely miss out on the action. But I certainly made nowhere near the gains I would have had I bought individual shares. Which makes me wonder, how did Nvidia get here, and what stock could be next? Crunching the numbers The numbers behind the hype are jaw-droppingly impressive. For the fiscal year ending January 2025, revenue reached $130bn, a staggering increase from $27bn just two years ago. Net income exploded from $4.3bn in 2022 to more than $70bn this year. And its margins are enormous — a return on equity of 115% and gross margins consistently above 70%. Yet despite the parabolic growth, I don't think it's entirely overvalued yet. In fact, I still think it's worth considering as a long-term investment. It's a world-class company with room to expand further and the global AI arms race is just getting started – with Nvidia at its core. Realistically, though, the biggest gains have already been made. Buying now means betting on continued dominance that may already be priced in, which is a risk. The stock trades at a price-to-earnings (P/E) ratio of 45 – not outrageous considering its growth, but not cheap either. So where should investors look if they want to catch the next killer growth stock before it becomes a trillion-dollar giant? Could SymphonyAI be next? One company on my radar is SymphonyAI, a private US firm reportedly preparing for a Nasdaq IPO later this year. It's not yet listed, but when it does go public, I'll be watching closely. Founded by billionaire Romesh Wadhwani, it specialises in applying AI to specific industry verticals – retail, finance, manufacturing, and healthcare. It doesn't build chips like Nvidia, but it builds the enterprise software that helps businesses harness AI to improve decision-making and productivity. Unlike many AI startups, SymphonyAI already has real revenues and customers. Its retail division serves over 1,200 brands, while its industrial arm works with giants like Nestlé and ArcelorMittal. While financials are still private, it reportedly generates hundreds of millions in annual revenue and is growing fast. If the IPO goes ahead this autumn, it could be one of the most closely watched tech listings of the year. Long-term mindset Nvidia's success was powered by timing, technology, and a growing reliance on data. It may still reward shareholders but the days of 10x returns are likely behind us. SymphonyAI might never reach Nvidia's heights but it could offer early-stage exposure to enterprise AI – the next leg of this growth story. If the valuation is right, it could turn out to be a once-in-a-decade opportunity. The post I missed Nvidia – could this be the next big US growth stock? appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool Mark Hartley has no position in any of the shares mentioned. The Motley Fool UK has recommended Apple, Microsoft, and Nvidia. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Tempus AI Stock Before Q2 Earnings Release: To Buy or Not to Buy?
Tempus AI, Inc. TEM is scheduled to report second-quarter 2025 results on Aug. 8. In the last reported quarter, the company's adjusted loss of 24 cents was narrower than the Zacks Consensus Estimate of a loss of 27 cents per share. Tempus AI, which went public in June 2024, exceeded estimates in two of the trailing four quarters and missed in two, the average negative earnings surprise being 2.07%. The Zacks Consensus Estimate for revenues is currently pegged at $299.3 million for the second quarter, implying an 80.4% improvement over the year-ago period. The Zacks Consensus Estimate for the second-quarter bottom line has narrowed by 4 cents to a loss of 23 cents per share over the past 90 days. TEM's Earnings Estimate Revision Trend Image Source: Zacks Investment Research Throughout the second quarter of 2025, Tempus AI had an impressive run on the bourses with a 34.5% gain. Despite macroeconomic challenges, including escalating trade tensions that broadly impacted the healthcare technology sector, the company witnessed strong momentum, primarily driven by a series of strategic acquisitions and partnerships in the field of AI-driven precision medicine. During this period, the company not only surpassed the 9.3% gain posted by the broader industry but also significantly outperformed the 3.4% decline of the Medical sector. The S&P 500 benchmark index gained 10.7% during this period. The company has also outperformed other players in the health infotech field, like 10x Genomics TXG and SOPHiA GENETICS SOPH. While TXG gained 33.5%, SOPH declined 2.3% during the said period. Q2 Price Comparison Image Source: Zacks Investment Research Let's see how things have shaped up for TEM shares prior to this announcement: Key Factors to Note Prior to Tempus AI's Q2 Earnings Tempus AI recently announced a three-year, $200 million foundational model partnership with AstraZeneca AZN and Pathos, which is expected to have contributed to its second-quarter performance. This non-exclusive data licensing agreement aims to develop the world's largest foundation model in oncology using over 300 petabytes of Tempus' multimodal data. With the first version of the model expected in 9-12 months, the deal is already transforming Tempus AI's data monetization trajectory. Management confirmed that revenues from this deal will be recognized ratably over the three-year term, starting in the second quarter. Tempus AI's hereditary testing segment, which contributed meaningfully to first-quarter growth, is expected to have maintained the trend this time too. When Tempus acquired Ambry Genetics, it guided mid-to-high teens growth, but the segment exceeded expectations with a 23% unit increase. While management has been cautious about projecting ongoing acceleration, they have also expressed confidence in the long-term potential for broader hereditary screening applications, ranging from cancer to cardiovascular and neurological risk. Tempus continued to expand its diagnostics portfolio with the recent FDA clearance of ECG-Low EF, its second AI-powered ECG tool for detecting low ejection fraction, further strengthening its position in cardiology and extending its reach beyond oncology. Meanwhile, the company launched xM for TRM, a liquid biopsy assay for monitoring immunotherapy response, which showed promising early data at ASCO 2025. These likely contributed to the second-quarter top line too. Tempus AI is advancing its digital health strategy by integrating Tempus One, its GenAI clinical assistant, into EHR systems, enabling physicians to query data, access guidelines and streamline workflows. The launch of Agent Builder for custom GenAI tools further deepens its role in clinical settings. Tempus One too is expected to have witnessed strong customer adoption during the second quarter. However, despite strong top-line growth and product momentum, Tempus AI in 2025 is facing a few near-term challenges. The company remains unprofitable, with an adjusted EBITDA loss of $16.2 million in the first quarter. Though the loss narrowed year over year, it raised questions about the timeline to profitability amid ongoing R&D investments. Additionally, while the AstraZeneca-Pathos foundation model deal is significant, its revenues will be recognized ratably over three years, limiting short-term financial impact. Further, investments tied to these updates, including product development, regulatory efforts, and marketing, are likely to have pushed operating expenses higher in the second quarter, putting some pressure on short-term profitability. Broader macroeconomic factors, like tariffs, hospital budget constraints and biotech funding trends, could also affect adoption rates. Expensive Valuation TEM's stock is currently overvalued compared to its industry, as shown in the chart below. TEM is currently trading at a forward 12-month price-to-sales (P/S) ratio of 6.86, a premium to the broader industry's average of 5.80X. It also trades higher than other industry players like 10x Genomics (2.70X) and SOPHiA GENETICS (2.40X). However, the stock is trading below its one-year median of 8.00X, suggesting that it has moderated somewhat from its historical highs. Image Source: Zacks Investment Research Our Take With the AI market projected to grow exponentially in the coming years, Tempus AI is well-positioned to capitalize on expanding opportunities. With a strong financial outlook and efforts to improve healthcare outcomes, TEM presents a unique opportunity for investors seeking high returns from the AI and healthcare sectors. Yet, despite the company's several recent upsides, its premium valuation and lack of near-term profitability are limiting this Zacks Rank #3 (Hold) stock's near-term gains. While current shareholders should hold their positions, new investors should wait for the stock to retract some of its recent gains, providing a better entry point. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report 10x Genomics (TXG) : Free Stock Analysis Report SOPHiA GENETICS SA (SOPH) : Free Stock Analysis Report Tempus AI, Inc. (TEM) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Entrepreneur
2 hours ago
- Entrepreneur
Cash Rush: Top Startup Funding Highlights (July 26–Aug 1)
From AI innovations to fintech powerhouses, these startups secured big investor bets this week. Opinions expressed by Entrepreneur contributors are their own. You're reading Entrepreneur India, an international franchise of Entrepreneur Media. The startup ecosystem saw a vibrant week of funding activity, with a mix of AI-driven innovations, fintech disruptors, and specialised platforms securing capital to fuel their next growth phase. From cybersecurity and semiconductor intelligence to edtech and gaming communities, these ventures are redefining industries with technology-first approaches and strong investor backing. Here's a snapshot of the week's biggest deals. SAFE – Cybersecurity Risk Quantification SAFE offers cybersecurity risk quantification and management services, enabling organisations to measure, prioritise, and mitigate cyber threats across digital infrastructure. Formerly known as Lucideus, Safe Security safeguards Fortune 500 companies with continuous risk assessments and actionable insights. Inception: 2012 2012 Founder: Saket Modi Saket Modi Based-out: California California Funding Amount: USD 70 Million USD 70 Million Investors: Avataar Ventures, Susquehanna Asia Venture Capital, NextEquity Partners, Prosperity7 Ventures, Eight Roads, John Chambers, Sorenson Capital Navi Technologies – Tech-Led Financial Services Navi operates a digital-first financial services platform offering personal and home loans via its NBFC arm, Navi Finserv. Its offerings extend to mutual funds, health insurance, and UPI-based payment solutions, making it a comprehensive financial ecosystem for retail consumers. Inception: 2018 2018 Founders: Sachin Bansal, Ankit Agarwal Sachin Bansal, Ankit Agarwal Based-out: Bengaluru Bengaluru Funding Amount: USD 20 Million USD 20 Million Investors: PhillipCapital, NDX Finserve, Aarpee Group, Ambit Finvest, and others Metaforms – AI Agents for Market Research Metaforms develops AI-driven agents that streamline market research workflows. From automating survey programming to data processing and vendor coordination, the platform enables faster turnarounds and scalability for research agencies. Inception: 2022 2022 Founders: Akshat Tyagi, Arjun S Akshat Tyagi, Arjun S Based-out: Bengaluru Bengaluru Funding Amount: USD 9 Million USD 9 Million Investors: Peak XV Partners, Nexus Venture Partners, Together Fund STAN – Social Platform for Gaming Creators STAN is a mobile-first platform empowering gaming creators, publishers, and communities through live audio, creator clubs, monetisation tools, and brand-led campaigns. It facilitates community building and engagement in gaming culture. Inception: 2022 2022 Founders: Parth Chadha, Rahul Singh, Nauman Mulla Parth Chadha, Rahul Singh, Nauman Mulla Based-out: Bengaluru Bengaluru Funding Amount: USD 8.5 Million USD 8.5 Million Investors: Google's AI Futures Fund, Bandai Namco Entertainment, Square Enix, Reazon Holdings, Aptos Labs, General Catalyst, GFR Fund, T-Accelerate Capital, Pix Capital SixSense – AI for Semiconductor Manufacturing SixSense uses AI to analyse semiconductor production data, detect critical defects, and predict process deviations. Its platform boosts throughput, reduces waste, and shifts manufacturing from reactive inspection to proactive control. Inception: 2018 2018 Founders: Akanksha Jagwani, Avni Agarwal Akanksha Jagwani, Avni Agarwal Based-out: Singapore Singapore Funding Amount: USD 8.5 Million USD 8.5 Million Investors: Peak XV's Surge, Alpha Intelligence Capital, Febe, and others Arivihan – AI-Powered Rural Learning Arivihan delivers personalised, AI-driven learning to students in smaller towns and rural areas. Its platform includes interactive lectures, instant doubt-solving, and tailored study plans for board and NEET exam preparation. Inception: 2024 2024 Founders: Ritesh Singh Chandel, Sonu Kumar, Rushabh Kothari Ritesh Singh Chandel, Sonu Kumar, Rushabh Kothari Based-out: Bengaluru Bengaluru Funding Amount: USD 4.17 Million USD 4.17 Million Investors: Prosus, Accel, GSF Investors – AI for Sales Performance provides a SaaS platform that boosts frontline sales productivity with personalised pitches, contextual coaching, and dynamic content. It serves major enterprises across BFSI, healthcare, consumer goods, and more. Inception: 2022 2022 Founders: Hanuman Kamma, Arun Subramanian Hanuman Kamma, Arun Subramanian Based-out: Mumbai Mumbai Funding Amount: USD 3.47 Million USD 3.47 Million Investors: Equentis Angel Fund These startups highlight how innovation and strategic funding continue to drive transformative solutions across industries.